Unlock Higher Productivity in Complex Protein Manufacturing With Peptones
Whitepaper
Published: February 13, 2025
Credit: Thermo Fisher Scientific
Biomanufacturers face increasing pressure to improve productivity and quality while maintaining consistent, scalable processes for complex protein therapies.
Traditional undefined additives like fetal bovine serum (FBS) can introduce variability and risk into manufacturing processes, compromising reproducibility and control. However, peptones are a powerful alternative that provide nutritional diversity and buffering capacity while delivering higher titers, improved protein quality and enhanced cell-specific productivity.
This whitepaper explores how peptones are revolutionizing biopharmaceutical manufacturing, offering a proven path to higher productivity and quality.
Download this whitepaper to learn:
How peptones can boost manufacturing productivity and reduce costs Key considerations for implementing peptones in complex protein therapeutic development Strategies for maintaining consistency and quality during scale-up of peptone-based processes
Peptones: a powerful tool for
manufacturing complex protein therapies
Introduction
Peptones have emerged as a valuable media additive for a range
of biopharmaceutical applications. They are a heterogeneous
mixture of polypeptides, oligopeptides, free amino acids, trace
metals, and nutrients derived from various sources, including
yeasts, plants, and animals. In contrast to more complex—
and consequently, more undefined—additives such as fetal
bovine serum (FBS), peptones can offer more consistency for
a manufacturing process, a crucial consideration for enabling
reproducibility and control.
Peptones possess a number of advantages for a
biopharmaceutical workflow. These supplements lack the
same potential for risk that researchers can encounter with
FBS, and they have achieved improved cell growth and viability
alongside lower variability, owing to more consistent processing.
Other key benefits of incorporating peptones into a cell culture
workflow include:
• Nutritional diversity, with many peptones containing a range
of components, including carbohydrates, vitamins, and trace
elements, among others
• Nutritional buffering capacity that improves cell health and
confers protection from toxicity
• Higher titers and improved protein quality compared to
chemically defined processes
• Better cell-specific productivity (Qp), a significant indicator of
the efficiency of a cell culture process
The benefits of peptones have already been realized for
hundreds of commercially approved applications. Ultimately,
these supplements hold promise not only for traditional
monoclonal antibodies (mAbs), where they have been proven
to improve process productivity and quality, but also for more
complex proteins like bispecific antibodies and antibody–drug
conjugates (ADCs).
White paper | Gibco Peptones
Boosting productivity and efficiency: the power
of peptones
The downstream efficiencies enabled by peptones are a key
consideration for developers. Their capacity for boosting Qp
can allow for more productive manufacturing within the same
infrastructure constraints as an existing process, creating
significant cost benefits by curtailing the need for additional
manufacturing capacity to meet product demand. The nutritional
benefits of peptones make them a ready solution for operators in
both early- and late-stage process development, allowing them
to achieve productivity goals with minimal resource expenditure.
Likewise, peptones can be flexibly incorporated into a cell culture
process. These supplements can also be used as part of a
media strategy wherein various peptones are blended to obtain
synergistic effects.
For those working with traditional mAbs and more complex
proteins alike, the primary development challenges are linked to
achieving target productivity and securing regulatory approval.
Because they are newer modalities compared to traditional
mAbs, bispecific antibodies and ADCs still have considerable
ground to cover in establishing manufacturing paradigms that
can achieve the necessary consistency and productivity. The
newness of these processes has made some in the space
reluctant to explore media components that are not fully
chemically defined, as they are concerned about the potential
regulatory implications of incorporating undefined additives such
as peptones into their workflows.
The possible benefits of peptones for improving the quality and
productivity of a process are as true for complex proteins as for
any other biopharmaceutical application. These components
are widely used in many commercial biopharmaceutical
applications, proving their capacity to pass regulatory muster.
Vetting a peptone’s suitability for one of these processes
is straightforward. First, developers must choose whether to
employ animal origin (AO) or animal origin–free (AOF) peptones.
This requires testing all suitable peptone candidates in either
category before potentially engaging in titration to narrow down
the best candidate, analyzing various concentrations and any
potentially beneficial combinations with other peptones.
Although many in the industry have expressed increasing interest
in AOF peptones, AO peptones can offer an effective and reliable
solution for many cell culture and bioprocessing applications.
AO peptones are frequently used to reduce or eliminate the
need for serum in some media formulations and can promote
strong cell growth and toxin titers for vaccine production.
Other considerations, such as the endotoxin level and bioburden
of a given peptone, may also drive developers to select an
ultrafiltered peptone, particularly for mammalian cell processes.
This evaluation must occur in conjunction with continual testing
of the key attributes of a drug substance. Ultimately, focusing on
titer alone during early optimization is shortsighted—any change
to a media feed has the potential to create a shift in one or more
of a drug’s key attributes. These shifts, if not monitored during
scale-up, can cause out-of-spec results during later development
stages, resulting in losses of time, money, and resources. The
complexities of both peptones and the protein therapeutics being
pursued today make this foundational characterization crucial.
Leveraging peptones for complex
biopharmaceutical production
Applications that require an increased focus on cost
considerations, such as viral vector gene therapies, may reap
additional benefits through incorporating peptones into a
media formulation. This is because these nutritionally diverse
supplements can enable greater titer gains while incurring
less expense than many other raw materials. Moreover,
because a peptone can sometimes supplant multiple other
discrete additives, operators can simplify their supply chain
and streamline workflows, potentially creating added time and
cost advantages.
Because the processes used to generate ADCs and bispecific
antibodies are more complex than those used for traditional
mAbs, there exists potential for additives like peptones to
help support improved early development by bolstering the
productivity of these applications. While any raw material can
introduce the potential for variability in a process, the tight
control suppliers have established over peptone production has
rendered these materials highly consistent. Peptones have been
incorporated into the manufacture of several blockbuster drugs,
proving their ability to support scale for products targeting large
doses or patient populations.
Transitioning to larger scales for these complex mAbs requires
the same focus on sources of variability throughout, but
the consistency of the peptones available for bioproduction
today makes them a less likely source of variability than many
developers may believe. As developers scale up their complex
mAbs, lot-to-lot consistency for these processes becomes even
more important. Peptones have come a long way over the last
60 years, and manufacturing processes have evolved with the
bioprocessing industry to produce peptones with tighter controls
and better consistency. It is critical to look at all key attributes
for impact based on lot-to-lot consistency, and there are many
techniques available to further control for variability in order to
arrive at a highly consistent, high-yield workflow.
2 Gibco Peptones thermofisher.com/peptones
Conclusion
As the demand for high-quality biotherapeutics continues to
grow, peptones, with their comparatively defined composition
and more consistent performance, will undoubtedly play an
increasingly vital role in the biomanufacturing landscape. These
additives, used in more than a hundred commercial products
spanning both human and animal drugs in a range of modalities,
are proven effective in boosting productivity and quality. Their
flexibility, cost efficiencies, and potential for simplifying workflows
and supply chains make them a valuable tool for not only
complex mAbs but also other emerging biotherapeutics such as
cell and gene therapies.
For Research Use or Further Manufacturing. Not for diagnostic use or direct administration into humans or animals.
© 2024 Thermo Fisher Scientific Inc. All rights reserved. All trademarks are the property of Thermo Fisher Scientific and its
subsidiaries unless otherwise specified. WTP-8865150 1024
Learn more at thermofisher.com/peptones